|
Dr. Mark Hayman is an Associate in the Patent Counseling & Prosecution practice group and a member of the Cooley Litigation department. Dr. Hayman joined the firm in 2007 and is a resident in the Boston office.
Dr. Hayman specializes in patent counseling and procurement in the areas of biotechnology, pharmaceuticals, and nanotechnology. Prior to joining Cooley, Dr. Hayman was an Associate in the Washington D.C. office of Sughrue Mion.
Dr. Hayman earned his Ph.D. in Microbiology from the University at Buffalo in 2000. Dr. Hayman's graduate research focused on identifying protein factors that are involved in an RNA editing process unique to trypanosome parasites and related organisms. Dr. Hayman co-authored several publications in peer-reviewed journals including the Journal of Biological Chemistry, Nucleic Acids Research, and Infection and Immunity. Dr. Hayman is particularly experienced with molecular biology, and protein and nucleic acid biochemistry.
Dr. Hayman has a degree in law from the University of Pittsburgh School of Law (2003), with a concentration in intellectual property.
Dr. Hayman frequently writes and presents on patenting inventions in the life sciences. His publications include:
- The ‘real world' utility of miRNA patents: lessons learned from expressed sequence tags, Nature Biotechnology Vol. 29, No. 2 (February 2011);
- The Emerging Product and Patent Landscape for Nanosilver-Containing Medical Devices, Nanotechnology Law & Business (2009);
- The Shaky Foundations of the Written Description Requirement, Managing Intellectual Property, IP Contacts Handbook (2005);
- Unpredictable Inventions; bionanotechnology inventions and the enablement challenges they present, Modern Drug Discovery (November 2004)
- Homology Claims Face New Equivalents Hurdles, The National Law Journal (December 2003).
Presentations include the 2005 WIPO National Seminar on Enhancing Global Competitiveness of Indian Life Sciences Industry Through Strategic Use of the Patent System (Delhi and Mumbai, India); and the Annual Meeting of the American Academy of Nanomedicine in 2006 and 2010.
Dr. Hayman has extensive experience in building patent portfolios to optimize product exclusivity positions for a wide array of technologies, including:
- protein and peptide therapeutics;
- RNA- and gene-based therapeutics;
- antibodies;
- diagnostic and prognostic tests, including genetic, gene expression, proteomic and cell-based tests for personalized medicine application;
- nucleic acid sequencing and detection technologies;
- recombinant protein production;
- biosynthetic processes and microbial strains;
- nanoparticle-based drug delivery platforms;
- wound care technologies.
Dr. Hayman is admitted to practice in Maryland and the District of Columbia, and is in the process of applying for admittance to the Massachusetts bar. Dr. Hayman is also registered to practice before the United States Patent and Trademark Office.
Education- University of Pittsburgh School of Law
JD, 2003 - State University of New York at Buffalo
PHD Microbiology, 2000 - State University of New York at Potsdam
BA Biology, 1994
Admissions
- District of Columbia
- Maryland
- Registered to practice before the United States Patent & Trademark Office (USPTO)
|